ALNY vs UI Comparison

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.

Ubiquiti Inc is a seller of equipment and provides the related software platforms through web stores. The group develops technology platforms for high-capacity distributed Internet access, unified information technology, and consumer electronics for professional, home, and personal use. Its solutions are: high-performance networking technology for enterprises, service providers, and consumers. target the enterprise and service provider markets through a community of service providers, distributors, value-added resellers, webstores, systems integrators, and corporate IT professionals, which it refers to as the Ubiquiti Community. It targets consumers through digital marketing, including through webstores, retail chains, and, to a lesser extent, the Ubiquiti Community.